Rexahn Pharmaceuticals (RNN) Receives Approval in Europe to Conduct a First-in-Human Trial of RX-3117
Up)
Rexahn Pharmaceuticals, Inc. (NYSE: RNN) today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn’s initial Clinical Trial Application (CTA). This allows Rexahn to initiate an exploratory first-in-human Phase I clinical trial of RX-3117.
RX-3117 is a small molecule antimetabolite for the treatment of solid tumors.
“Preclinical studies demonstrate RX-3117 to have exciting anti-cancer properties, and we look forward to moving this compound into clinical development,” said Rick Soni, President and COO of Rexahn. “We will continue to develop RX-3117, which has potential therapeutic applications in a broad range of cancers, including colon, lung and pancreatic cancer.”
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
RX-3117 is a small molecule antimetabolite for the treatment of solid tumors.
“Preclinical studies demonstrate RX-3117 to have exciting anti-cancer properties, and we look forward to moving this compound into clinical development,” said Rick Soni, President and COO of Rexahn. “We will continue to develop RX-3117, which has potential therapeutic applications in a broad range of cancers, including colon, lung and pancreatic cancer.”
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Auxilium Pharma (AUXL), Glaxo (GSK) Enter Testim 1% Co-Promotion Agreement
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
